How Experience & Capacity Influence Biologic API Outsourcing
Source: ISR Reports
In Q2, 2018, ISR asked 48 outsourcers of biologic API to select from four different reasons that manufacturing is split between in-house and external resources. The data below show how respondents rated their organization’s experience and capacity with respect to outsourcing large molecule drug substance, with the majority (48%) stating their company has adequate experience but lacks manufacturing capacity.
access the Infographic!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.
Subscribe to Bioprocess Online
X
Subscribe to Bioprocess Online
ISR Reports
This website uses cookies to ensure you get the best experience on our website. Learn more